A cathepsin K inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Balicatib

Item No. 17995

Technical Information
Formal Name
N-[1-[[(cyanomethyl)amino]carbonyl]cyclohexyl]-4-(4-propyl-1-piperazinyl)-benzamide
CAS Number
354813-19-7
Synonyms
  • AAE581
Molecular Formula
C23H33N5O2
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 25 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 10 mg/mlEthanol: 0.5 mg/ml
λmax
202, 297 nm
SMILES
CCCN1CCN(C2=CC=C(C(NC3(C(NCC#N)=O)CCCCC3)=O)C=C2)CC1
InChi Code
InChI=1S/C23H33N5O2/c1-2-14-27-15-17-28(18-16-27)20-8-6-19(7-9-20)21(29)26-23(10-4-3-5-11-23)22(30)25-13-12-24/h6-9H,2-5,10-11,13-18H2,1H3,(H,25,30)(H,26,29)
InChi Key
LLCRBOWRJOUJAE-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Balicatib is a potent inhibitor of cathepsin K (IC50s = 1.4, 56, and 480 nM for human, rat, and mouse forms, respectively).1,2 it is at least 100-fold selective for cathepsin K over cathepsins B, L, and S.2 Balicatib has a basic lipophilic nature, resulting in lysosomal trapping and increased selectivity for lysosomal cathepsin K.1,2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Desmarais, S., Black, W.C., Oballa, R., et alEffect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol. Pharmacol. 73(1), 147-156 (2008).

    2. Falgueyret, J.-P., Desmarais, S., Oballa, R., et alLysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48(24), 7535-7543 (2005).